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a b s t r a c t
The proteoglycan aggrecan is a prominent component of the extracellular matrix in growth plate
cartilage. A naturally occurring, recessive, perinatally lethal mutation in the aggrecan core protein gene,
cmdbc (Acancmd-Bc), that deletes the entire protein-coding sequence provided a model in which to
characterize the phenotypic and morphologic effects of aggrecan deletion on skeletal development. We
also generated a novel transgenic mouse, Tg(COL2A1-ACAN), that has the chick ACAN coding sequence
driven by the mouse COL2A1 promoter to enable the production of cmdbc/cmdbc; Tg(COL2A1-ACAN)
rescue embryos. These were used to assess the impact of aggrecan on growth plate organization,
chondrocyte survival and proliferation, and the expression of mRNAs encoding chondrocyte differentia-
tion markers and growth factors. Homozygous mutant (cmdbc/cmdbc) embryos exhibited severe defects
in all skeletal elements with deformed and shortened (50%) limb elements. Expression of aggrecan in
rescue embryos reversed the skeletal defects to varying degrees with a 20% increase in limb element
length and near-full reversal (80%) of size and diameter of the ribcage and vertebrae. Aggrecan-null
growth plates were devoid of matrix and lacked chondrocyte organization and differentiation, while
those of the rescue embryos exhibited matrix production concomitant with partial zonation of
chondrocytes having proliferative and hypertrophic morphologies. Deformation of the trachea, likely
the cause of the mutation's lethality, was reduced in the rescue embryos. Aggrecan-null embryos also
had abnormal patterns of COL10A1, SOX9, IHH, PTCH1, and FGFR3 mRNA expression in the growth plate.
Expression of chick aggrecan in the rescue embryos notably increased COLX expression, accompanied by
the reappearance of a hypertrophic zone and IHH expression. Signiﬁcantly, in transgenic rescue embryos,
the cell death and decreased proliferation phenotypes exhibited by the mutants were reversed; both
were restored to wild-type levels. These ﬁndings suggest that aggrecan has a major role in regulating the
expression of key growth factors and signaling molecules during development of cartilaginous tissue and
is essential for proper chondrocyte organization, morphology, and survival during embryonic limb
development.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The development of the skeleton involves a highly regulated,
spatially organized series of events that require the precise
temporal control of a multitude of morphogens, growth factors,
transcription factors, and mechanical signaling pathways. Chon-
drodysplasias and other cartilage defects, frequently caused by
perturbations of the extracellular matrix (ECM), are a relatively
rare group of genetic disorders with no treatment options thus far.
An understanding of the mechanisms and signaling pathways
involved in these disease processes is essential to ﬁnding potential
therapeutic targets.
Long bone formation begins with the condensation of
mesenchymal cells that undergo chondrogenic differentiation in
the early limb bud under the appropriate signals; these primitive
chondrocyte precursors create the scaffold upon which the long
bones of the skeleton develop and elongate. The most rapid linear
endochondral growth occurs prenatally and is dependent upon
proper organization and maturation of chondrocytes, a process
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that occurs in multiple histologically distinct stages in the epiphy-
seal growth plates of long bones. Resting chondrocytes, found near
the distal end of the epiphysis, have a small, round morphology,
divide slowly, and serve as a stem-cell-like population for the
growth plate. The resting chondrocyte population gives rise to and
controls the orientation of the proliferative zone chondrocytes
(Abad et al., 2002). Chondrocytes enter the proliferative state,
assume a characteristic ﬂattened morphology, begin to rapidly
divide, and secrete abundant extracellular matrix components.
Elongation of the limb element occurs predominantly during this
phase as the chondrocytes form clonal columns parallel to the
longitudinal axis of the bone. After several mitoses, chondrocytes
mature to prehypertrophic and then to large, spherical hyper-
trophic cells which increase their intracellular calcium levels,
commencing the mineralization process of the surrounding extra-
cellular matrix (ECM) (Iannotti, 1989). Ultimately, hypertrophic
chondrocytes undergo apoptosis and resorption at the vascular
invasion front, where osteoblasts, osteoclasts, and chondroclasts
are recruited to complete the transformation of the extracellular
matrix into mineralized bone tissue (Lewinson 1992). This series of
events is tightly regulated by the interplay of systemic and local
paracrine factors, growth regulators, and mechanical forces that
together direct the differentiation and gene expression proﬁle of
growth plate chondrocytes (Wagner and Karsenty, 2001).
Although most studies focus on limb development, the endochon-
dral growth processes of other skeletal elements (i.e., rib cage)
follow similar regulatory paradigms and can be severely affected
by genetic mutations.
The ECM plays a critical role not only in the structural support
of chondrocytes but also by serving as a medium in which
signaling molecules and growth factors are able to diffuse through
the avascular cartilage tissue to target cells (Cortes et al., 2009).
The ECM is composed predominantly of collagens, proteoglycans,
hyaluronan, and link protein with smaller amounts of other
matrix-speciﬁc proteins (Schwartz and Domowicz, 2002). Differ-
ent proteoglycans have unique expression patterns during skeletal
development that are regulated spatially and temporally (Ovadia,
Lash, 1980). Versican, a large chondroitin sulfate proteoglycan
(CSPG) expressed in mesenchymal condensations of the pre-
cartilaginous anlagen, is downregulated as aggrecan, the predo-
minant CSPG in cartilage, is signiﬁcantly upregulated upon chon-
drogenic differentiation (Kimata et al., 1986; Schwartz et al., 1993).
As endochondral ossiﬁcation of the cartilage elements ensues, the
expression of aggrecan by differentiating chondrocytes predomi-
nates over other proteoglycans (Ovadia, Lash, 1980).
Aggrecan has a variety of important functions in the growth plate
aside from its structural role in the ECM. The numerous sulfated
glycosaminoglycans (GAG), attached to the core protein of aggrecan
create a large, highly negatively-charged molecule that enables
hydration of the cartilage tissue as well as binding of growth factors
and morphogens crucial to chondrocyte maturation and function
(Cortes et al., 2009; Ruoslahti and Yamaguchi, 1991). In particular,
our laboratory has provided evidence that proper sulfation patterns
of the GAG chains attached to aggrecan are essential for postnatal
morphogen gradient formation in the growth plate, further empha-
sizing the role of proteoglycans in regulation and modiﬁcation of
normal bone growth (Cortes et al., 2009). Mutations in the aggrecan
gene are the cause of several chondrodysplasias and inherited
skeletal disorders in humans (Schwartz and Domowicz, 2002;
Schwartz and Domowicz, 2014), including spondyloepimetaphyseal
dysplasia with premature and severe osteoarthritis and osteochon-
dritis dissecans (Gleghorn et al., 2005; Stattin et al., 2010; Tompson
et al., 2009). Other cartilage disorders, such as pseudoachondropla-
sia and those involving impaired sulfation of proteoglycans, are
caused in part by improper processing and intracellular trafﬁcking of
aggrecan, resulting in retarded bone growth (Kwak et al., 2009;
Vissers et al., 2011). Despite the increasing association of aggrecan
with skeletal disorders, a mechanistic understanding of how aggre-
can inﬂuences growth plate cytoarchitecture and organization
during development remains limited.
We have previously reported on spontaneous autosomal recessive
mutations in the chick and mouse aggrecan core protein genes that
cause severe chondrodystrophies with perinatal lethality. The chick
mutation nanomelia is a single-base substitution which introduces a
premature stop codon in the aggrecan gene (Li et al., 1993), resulting in
a severely truncated core protein that is not glycosylated or trans-
ported through the secretory pathway, as it does not possess the G3
domain required for translocation from the endoplasmic reticulum
(Domowicz et al., 2000; Vertel et al., 1994). This mutation renders the
nanomelic chick a functional aggrecan-null model, grossly character-
ized by severe reduction in the size of the head, trunk, and limbs.
Growth plates of these embryos contain homogenous populations of
small, round chondrocytes, are devoid of extracellular matrix, and
have signiﬁcantly altered morphogen gradient distributions and gene
expression proﬁles of critical chondrocyte regulators (Domowicz et al.,
2009; Schwartz and Domowicz, 2002; Schwartz and Domowicz,
2014). Similarly, two different recessive mutations in the mouse
aggrecan core protein each results in cartilage matrix deﬁciency
(cmd) and produce consistent phenotypes, that is, shortened trunk,
cleft palate, extremely truncated limbs, and protruding abdomen (Bell
et al., 1986; Brennan et al., 1983; Rittenhouse et al., 1978). One of these
mutations, Acancmd, is a 7-base-pair deletion in exon 5 of the aggrecan
gene, which results in a truncated protein product (Watanabe et al.,
1994). Our laboratory previously identiﬁed and sequenced a separate
recessive mutation, cmdbc (or Acancmd-Bc), which causes visible skeletal
deformations beginning at embryonic day 15. The mutation is a
deletion that begins in intron 1 of the mouse aggrecan gene and
removes exons 2 through 18, the entire protein-coding sequence
(Krueger et al., 1999). To date, the morphological characterization,
gene expression analysis, and cellular consequences of these muta-
tions in the aggrecan-null mouse embryonic growth plate are not well
deﬁned; the present study, using mice with the cmdbc mutation,
provides that characterization.
Although our previous observations in the nanomelic chick
demonstrated that loss of aggrecan is accompanied by signiﬁcant
abnormalities in chondrocyte maturation, proliferation, and survival,
it is not known which of these phenotypes are primary effects or
secondary to perturbation of the ECM environment caused by the
aggrecan deﬁciency. To understand how aggrecan inﬂuences carti-
lage growth plate organization and cytoarchitecture, we generated a
novel, tissue-speciﬁc transgenic model, cmdbc/cmdbc, Tg(COL2A1-
ACAN), referred in this paper as Agc/þ , in which chick aggrecan is
expressed under the control of the collagen type II, alpha 1(COL2A1)
promoter. This transgenic mouse line was successively crossed with
þ/cmdbc mice to generate embryos lacking endogenous mouse
aggrecan production while expressing chick aggrecan speciﬁcally in
cartilage tissue at the onset of COL2A1 promoter activation during
day 10 of development (i.e., cmdbc/cmdbc, Agc/þ). Partial rescue of the
cmd phenotype was obtained conﬁrming aggrecan to be an essential
ECMmolecule that inﬂuences chondrocyte survival, promotes hyper-
trophic maturation, and contributes to the proper morphogen,
growth factor, and transcription factor expression proﬁle in the
developing growth plate.
Materials and methods
Mouse model and husbandry
To generate cartilage-speciﬁc, aggrecan-expressing transgenic
mice, the plasmid pBluescript KSþ (pBS) was ﬁrst modiﬁed by
inserting a bovine growth hormone poly A tail between PacI and
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XhoI restriction sites, and a 200 base pair (bp) splice acceptor was
introduced between SpeI and HindIII. The chondrocyte-speciﬁc
collagen type II, alpha 1 (COL2A1) promoter was digested from
the vector p3000i3020Col2a-βgeo (kindly provided by Dr. Veroni-
que Lefebvre at Cleveland Clinic) utilizing NotI and XbaI, and cloned
into NotI and SpeI sites of the pBS vector to create the plasmid
pBSCol2a1. The 6.3 kb chicken aggrecan cDNA was then cloned into
the pBS-Col2a1 plasmid in two fragments using the In-fusion PCR
system (Clontech) (Cortes et al., 2012). The construct was puriﬁed
and utilized for pronuclear injection into one-cell mouse embryos
to generate three heterozygous founder lines on the C57BL/6
background that express chick aggrecan driven by the COL2A1
promoter (Fig. 1).
The cartilage matrix deﬁciency allele utilized in these studies,
cmdbc, a mutation causing the deletion of exon 2 through exon 18 in
the aggrecan gene which is perinatally lethal (Krueger et al., 1999),
was initially found on a BALB/c background, and was subsequently
backcrossed more than 20 generations onto the C57BL/6 background
prior to experimentation. To generate embryonic mice which are
homozygous for the cmdbc mutation but express chicken aggrecan,
heterozygous (þ/cmdbc) females were crossed with heterozygous
males that also carried the chicken aggrecan transgene (þ/cmdbc:
Agc/þ). Litters were harvested from pregnant females at 18.5 days
post-coitum (dpc), which were sacriﬁced according to University of
Chicago Institutional Animal Care and Use Committee protocol.
To identify chick-aggrecan-transgenic animals and mice hetero-
or homozygous for the cmdbc mutation, the following speciﬁc
primers were used to genotype the embryos from 18.5 dpc litters:
Aggrecan transgene: Forward 50–CTAGAGATCAGTGGACTGCCT-30;
Reverse 50–TCTGGAGCTGTGCAGTCTAGTGG-30
cmdbc allele: Forward (mutant) 50–GGTAAGCCAGGAGCCA-
GAACTGTGCCCAGA-30; Reverse (wild type) 50- GACAATCCCTCTTA-
CACCTCCCCTACTCAA-30; Reverse (mutant) 50- GCCCAGCCTCGTC
TAAGAGACCCTGGCACT-30
Southern blot analysis
Chick aggrecan transgenic animals were initially identiﬁed by
Southern blot analysis according to standard protocol (Sambrook
and Russell, 2001) with minor modiﬁcations. Brieﬂy, restriction
fragments from XbaI- and KpnI- digested tail DNA were separated
on an agarose gel, denatured and transferred to a nylon mem-
brane. Transferred DNAwas UV cross-linked to the membrane, and
a probe homologous to a 392 bp segment of the chick aggrecan
coding sequence, shown in Fig. 1A, was generated by PCR using the
following primers: forward, 50–CTAGAGATCAGTGGACTGCCT-30;
and reverse, 50–GGTCTGGAGCTGTGCAGTCTAGTGG-30. The PCR
product was puriﬁed and radioactively labeled with 32P-dCTP
(using the Random Primed DNA labeling kit (Roche)). The probe
was hybridized to the membranes at 68 1C for one hour in
hybridization solution (QuickHyb, Stratagene) containing dena-
tured salmon sperm DNA, the blots were washed at high strin-
gency, and bound probe was detected on X-ray ﬁlm. To infer
transgene copy number, it was assumed that the haploid content
of a mammalian genome is 3109 bp and that the mass of the one
copy standard was represented by 26.6 pg of the original construct
per 10 mg genomic DNA. This mass was used to calculate the copy
standards by digesting 10 mg of genomic DNA from wild-type
littermates with 5, 10, and 50 copies of the pBSCol2a1-chick
aggrecan plasmid construct. Ten microgram of tail DNA from the
three transgenic founder lines Agc17, Agc18, and Agc1283 was
digested and the expected 2.8 kb band's density was compared
with the standards to estimate transgenic copy number. These
three colonies have been maintained for over 5 years with
comparable levels of transgene expression and consistent South-
ern blot proﬁles, which supports the assumption that the trans-
gene has a single integration site as has been reported for
transgenic animals derived by similar methods (Brinster et al.,
1981; Brinster et al., 1985; Lacy et al., 1983).
Fig. 1. Generation of chick aggrecan transgenic mice. (A) Schematic representation of the Col2a1-chick aggrecan DNA construct utilized for generation of Agc17/þ , Agc18/þ ,
and Agc1283/þ transgenic mice. The construct consists of a 3 kb Col2a1 promoter (hatched box), 237 bp exon 1 (gray box), a 3.02 kb segment of Col2a1 intron 1, and the 6.3 kb
chick aggrecan gene. Restriction sites used in cloning are depicted and described in the Materials and Methods section. (B) Representative Southern blot using a 32P-dCTP
labeled probe (panel A, red box) of genomic DNA from each of the Agc/þ transgenic lines following XbaI and KpnI digestion (panel A, red). Transgenic line Agc17/þ contained
the highest copy number with greater than 50 copies. Representative immunohistochemistry experiments using monoclonal antibodies against chick aggrecan (S103L, C)
and chondroitin-6-sulfate (D) are shown for distal femurs of 18.5 dpc embryos of each genotype from the same litter. SA¼splice acceptor site.
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Skeletal preparations
At 18.5 dpc, embryos were ﬁxed in 95% ethanol for 24 hours,
then eviscerated and placed in Alcian blue staining solution (20%
glacial acetic acid/80% ethanol/0.015% Alcian blue 8GX) for one
week. The embryos were further dehydrated in three changes of
95% ethanol over the course of one week, then cleared in 1%
potassium hydroxide (KOH). Staining of mineralized tissue
involved placing embryos in 0.001% Alizarin Red-0.5% KOH,
followed by passing them through a graded series of KOH solu-
tions (0.5% to 0.05%) for ﬁnal clearing and storing in glycerol/PBS/
formaldehyde 10:1:1. Limb elements were dissected free and
imaged on a stereoscope in order to quantify individual limb
lengths (proximal epiphysis to distal epiphysis) using the mea-
surement tool in Adobe Photoshop. Statistical signiﬁcance across
genotypes for each individual element was analyzed using a one-
way ANOVA with Tukey's post-hoc testing.
mRNA in situ hybridization
Antisense RNA probes for the collagen type X, alpha 1
(Col10a1), collagen type II, alpha 1 (Col2a1), SRY (sex determining
region Y)-box 9 (Sox9), Indian hedgehog (Ihh), patched homolog 1
(Ptch1), and ﬁbroblast growth factor receptor 3 (Fgfr3) gene
transcripts were transcribed from cDNA fragments using digox-
ygenin (DIG) labeled nucleotide mix and T7 or SP6 polymerase
(Roche) as previously described (Cortes et al., 2009; Domowicz
et al., 2008). Mouse hind limbs (18.5 dpc) were dissected free,
ﬁxed in 4% paraformaldehyde/PBS at 4 1C, sunk in 20% sucrose/10%
formalin in PBS, embedded in gelatin, and 40 mm serial sections
were cut, mounted onto silane-treated slides, and dried overnight.
Sections were hybridized with RNA antisense probes at 70 1C for
16 hours followed by four post-hybridization stringent washes
(50% formamide, 2 SSC, 1% SDS). Hybridization signals were
detected by incubating sections with alkaline phosphatase-anti-
DIG Fab fragments (Roche) overnight at 4 1C. The colorimetric
reaction was carried out using NBT-BCIP as substrates.
TUNEL staining
Hind limb tissue sections from 18.5 dpc embryos were depar-
afﬁnized and permeabilized with 0.1% Triton-X. Apoptotic chon-
drocytes were detected in the sections using the in situ Cell Death
Kit (Roche) following the manufacturer's instructions. Sections
were counterstained with DAPI and mounted. Negative control
slides were treated with the incubation buffer in the absence of
enzyme, as suggested by the manufacturer's protocol. TUNEL-
positive nuclei were counted in the distal femoral growth plates
using ImageJ software (Schindelin et al., 2012), and data were
analyzed for statistical signiﬁcance using a one-way ANOVA with
Tukey's post-hoc testing.
Immunohistochemistry
Limbs were dissected free and ﬁxed in 4% paraformaldehyde
overnight at 4 1C. Parafﬁn sections (5 μm) were permeabilized with
0.1% Triton-X followed by digestion with 0.5 U/ml chondroitinase
ABC (Seikagaku). Sections were stained with anti-S103L, a mono-
clonal antibody speciﬁc for chick aggrecan (Krueger et al., 1990),
anti-phospho-histone H3 (Ser10) polyclonal antibody (Upstate Bio-
technology), anti-chondroitin-4-sulfate antibody (2B6 clone) and
anti-chondroitin-6-sulfate antibody (3B3 clone) (Seikagaku) in 5%
serum overnight at 4 1C. Sections were washed and incubated with
AlexaFluor ﬂuorescent secondary antibodies (Invitrogen), counter-
stained with DAPI and mounted. Positive phospho-histone H3 nuclei
were quantiﬁed in the 18.5 dpc embryos’ distal femurs of using
ImageJ software, and data were analyzed for statistical signiﬁcance
using a one-way ANOVA with Tukey's post-hoc testing.
Results
Generation of chicken aggrecan transgenic and aggrecan-null mutant
mouse embryos
In order to investigate the contribution of the cartilage-speciﬁc
proteoglycan aggrecan in growth plate maturation and skeletal
development, a chick-aggrecan expressing transgenic mouse was
created by cloning the full-length chicken aggrecan cDNA (Cortes
et al., 2012) into a vector containing a 3 kb Col2a1 promoter and a
3 kb segment of intron 1, previously shown to be required for
efﬁcient cartilage-speciﬁc expression (Zhou et al., 1995). The con-
struct (Fig. 1A) was microinjected into fertilized single cell mouse
embryos, generating three heterozygous founder lines: Agc17/þ ,
Agc18/þ , and Agc1283/þ . All Col2a1-chick aggrecan transgenic mice,
as well as mice heterozygous for the cmdbc mutation, were pheno-
typically indistinguishable from wild-type littermates at 18.5 dpc and
postnatally, and no gross or quantitative skeletal abnormalities were
observed (data not shown). Each genotype was analyzed for potential
differences in mouse aggrecan expression by in situ hybridization
and quantitative RT-PCR (Supplemental Figs. 1 and 2). In situ
hybridization revealed no major differences in the expression pattern
of endogenous mouse aggrecan between þ/þ , cmdbc/þ , and Agc/þ ,
embryos at 18.5 dpc, (Supplemental Fig. 1), as well no signiﬁcant
difference in the relative expression of mouse aggrecan across
genotypes was demonstrated by quantitative RT-PCR (Supplemental
Fig. 1).
Southern blot analysis demonstrated that founder line 17 retained
the highest copy number of the transgene with greater than 50
copies (Fig. 1B), and therefore this line was utilized for all remaining
experiments. Successive crossing of Agc17/þ mice with cmdbc/þ
generated mice concurrently heterozygous for the cmdbc mutation
and Agc17 transgene. These mice were crossed with cmdbc/þ mice to
generate litters including “mutant” embryos (cmdbc/cmdbc), which
completely lack endogenous aggrecan due to a mutation that results
in the deletion of exons 2 through 18 (Krueger et al., 1999), and
“rescue” embryos (cmdbc/cmdbc;Agc/þ) which lack endogenous
mouse aggrecan but express the chick aggrecan transgene.
Cartilage-speciﬁc protein expression of the chick aggrecan transgene
was veriﬁed in the limbs of founder line 17 (Fig. 1C, left panel) and in
the rescue animals derived from line 17 (Fig. 1C, right panel) using
the S103L monoclonal antibody, which recognizes a speciﬁc epitope
on the core protein of chick aggrecan exclusively (Krueger et al.,
1990). Limbs from 18.5 dpc rescue embryos show robust extracellular
S103L staining comparable to that for the transgenic founder line,
indicating that efﬁcient expression and secretion of chick aggrecan
protein was achieved in embryos lacking mouse aggrecan. We also
performed qRT-PCR for relative quantitation of chick aggrecan and
found no differences in chick aggrecan expression levels between
Agc17/þ and rescue embryos (Supplemental Fig. 2). However, when
analyzing the gene expression ratio of chick vs. mouse aggrecan in
transgenic line 17 cartilage, we found that there is ﬁvefold less chick
aggrecan mRNA expressed compared to endogenous mouse aggrecan
mRNA at 18.5 dpc, indicating that the aggrecan transgene does not
achieve the same levels of expression as endogenous mouse
aggrecan.
Although chick aggrecan core protein was synthesized and
secreted, it was necessary to demonstrate that the protein under-
goes extensive post-translational addition of chondroitin sulfate
side chains. Therefore, we examined overall levels of chondroitin-
6-sulfate and chondroitin-4-sulfate in the growth plates of foun-
der line 17 (Fig. 1D, upper left panel and Supplemental Fig. 3,
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respectively), in rescue embryos, mutant embryos, and represen-
tative embryos of different genotypes from the same litter.
Compared to all other genotypes, mutant growth plates exhibit
very low chondroitin-6- and chondroitin-4-sulfate staining in
growth plate cartilage, as expected due to the lack of aggrecan in
the matrix. Patterns of chondroitin-6-sulfate detected in the
rescue embryos lacking endogenous aggrecan were comparable
to that of the wild-type lines and the staining intensity of
chondroitin 4-sulfate increased in rescue growth plates compared
to that of mutants, indicating that the chick aggrecan protein
expressed by transgenic rescue embryos contains chondroitin
sulfated moieties.
Chick aggrecan transgene expression in cmdbc/cmdbc embryos
increases limb length and partially restores skeletal element Alizarin
red staining patterns
Dysregulation of several genes that affect the formation of
appendicular and axial skeletal elements has been described; few
of these have been veriﬁed by transgene-rescue approaches.
Analysis of skeletal preparations from 18.5 dpc embryos was
carried out using Alcian blue and Alizarin red to stain cartilage
and calciﬁed tissue, respectively. Examination of individual axial
and appendicular skeletal elements revealed improved skeletal
element formation compared to mutants. The cmdbc/cmdbc mutant
embryos had a 45–55% decrease in the length of the long-bone
elements of the forelimb and hindlimb (Fig. 2A, F) compared to
wild-type (þ /þ) embryos, while in the cmdbc/cmdbc;Agc17/þ
rescue embryos, the overall length of the femur and tibia increased
18% and the length of the humerus and ulna increased by 21%
compared to mutant embryos (Fig. 2F).
Abnormal cervical spine alignment and positioning of the atlas
and axis (Fig. 2A, B) were observed in mutant embryos; these
defects were largely corrected in rescue embryos. In E18.5 dpc
wild-type embryos, the center of the cervical vertebrae are
cartilaginous (Fig. 2C), while mutant embryos possess dual Ali-
zarin red-positive sites in the same regions (Fig. 2C, arrows). The
cartilaginous phenotype is largely restored in the rescue mice,
which exhibit only a single premature ossiﬁcation center within
the center of the cervical vertebrae. Normal staining patterns are
Fig. 2. Skeletal element analysis in aggrecan null cmdBc/cmdBc embryos and transgenic cmdBc/cmdBc;Ag17/þ rescue mice. (A) Comparison between whole skeletons of wild-
type (þ/þ), mutant (cmdBc/cmdBc), and rescue (cmdBc/cmdBc;Agc17/þ) embryos harvested 18.5 dpc and stained with Alizarin red (presumed ossiﬁed areas) and Alcian blue
(cartilage). Individual skeletal element dissections were analyzed for staining patterns and overall size for the cervical spine (B-C), lumbar spine (D), ribcage (E), forelimb
digits (G), hindlimb digits (H), and sternum (I). Arrows demonstrate Alizarin red staining differences in the spine and digits, and sternum segments are labeled to
demonstrate abnormal staining patterns of the third through ﬁfth sternebrae in mutants (I). Quantiﬁcation of long bone deﬁciencies found a 50% decrease in length of
mutant limbs, with a 20% improvement in rescue mice (F). n¼6–18 embryos/genotype, npo0.001 vs. þ/þ , #po0.05 vs. cmdBc/cmdBc, one-way ANOVAwith Tukey's post-hoc
testing.
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also restored in the center of the lumbar spine by transgene
expression compared to mutant embryos, which display aberrant
Alizarin red staining patterns within the centrum and neural arch
(Fig. 2D, arrow) and decreased vertebral body size.
The digits of the forelimbs of rescue embryos are lengthened
compared to mutants and display enhanced Alcian blue staining
intensity, indicative of the increased proteoglycan content of the
ECM (Fig. 2G). Ossiﬁcation centers in the distal phalanx of the
forelimb that are lost in aggrecan-null mutants are restored in
rescue embryos (Fig. 2G, arrows). Transgene expression did not
rescue the premature bone deposition observed in the tarsals of
the hindlimb (Fig. 2H, arrows); however, increased Alcian blue
stain intensity is again observed.
Comparison of wild-type and mutant embryo skeletons
demonstrates the severely shortened (by 50%), decreased in
diameter, and bell-shaped rib cage in mutant embryos (Fig. 2E).
Transgene expression in the rescue embryos signiﬁcantly
increased the intercostal spaces, overall size (80%), and diameter
of the rib cage compared to mutant embryos. Compared to wild-
type, mutant embryonic sterna have highly irregular patterns of
staining. Increased Alizarin red staining between the third, fourth,
and ﬁfth sternebrae, and absence of Alcian blue-positive cartilage,
suggested possible premature bone formation (Fig. 2I). In order to
verify whether these staining patterns were indicative of preco-
cious ossiﬁcation of the sternebrae, hematoxylin and eosin
(H&E) staining and von Kossa staining was performed on serial
sections of sterna from wild-type, mutant, and rescue embryos
(Supplemental Fig. 4). Interestingly, the Alizarin red-positive areas
in the mutant are not predominantly calciﬁed as seen in the wild-
type and rescue sterna, but rather consist of irregular-appearing
cartilage. Aberrant chondrocyte morphology, organization, and
matrix deposition are also seen in mutant sterna. These anomalies
are improved in the sternum of rescue embryos, which exhibit the
expected patterns of sternebrae ossiﬁcation found in wild-type
embryos, despite the sustained reduction in total sternum length.
Chondrocyte cytoarchitecture and growth plate morphology are
improved in rescue embryos
To investigate the impact of reintroducing aggrecan into the
extracellular matrix on chondrocyte cytoarchitecture and growth
plate organization, histological sections of 18.5 dpc femurs from
wild-type, mutant, and rescue embryos were H&E-stained to detect
the organization of distinct chondrocyte populations within each
growth plate (Fig. 3A C). In wild-type embryos, immature resting
(R) chondrocytes are located closest to the articular surface of the
bone (Fig. 3A), and display the typical small, round morphology and
homogenous distribution within the extracellular matrix. As these
chondrocytes enter the cell cycle and begin to proliferate (P), they
assume a discoid shape and align into the characteristic columnar
organization (Fig. 3A’, red outline) with abundant extracellular
matrix production that is required for growth plate elongation
(arrows). Finally, the chondrocytes reach the post-mitotic hyper-
trophic stage of maturation (H) and are identiﬁed by their enlarged
volume, spherical shape, increased cytoplasmic to nuclear ratio, and
decreased interterritorial matrix (Fig. 3A’, outlined by black box).
While the chondrocyte zones within growth plates of wild-type
embryos are clearly deﬁned, the growth plates of mutant embryos
(Fig. 3B) appear homogenous and devoid of zone organization and
cytoarchitecture. The chondrocytes are small, round cells dis-
persed randomly throughout the markedly truncated epiphyseal
growth plates and are indistinguishable from one zone to the next.
Mutants display small areas of hypocellularity in arbitrary regions
of the resting zone (Fig. 3B, white arrows), while the rest of the
growth plate exhibits a severe deﬁciency in matrix production,
evident by the markedly increased cell density (Fig. 3B’, arrow
heads). In addition, mutant cartilage exhibits very few cells that
can be distinguished as “hypertrophic” chondrocytes at the
chondro-osseous junction.
Rescue embryonic growth plates have improved chondrocyte
zonation and partial restoration of the associated cytoarchitecture
of the proliferative and hypertrophic zones. As shown in Fig. 3C, there
is an increase in the overall size of the epiphyseal growth plate of the
femur compared to the mutant samples, and a decrease in cell
density. Though smaller and less deﬁned than in wild-type embryos,
a proliferative zone is evident in rescue growth plate cartilage, as
noted by formation of small columns of cells and ﬂattened chon-
drocyte morphology (Fig. 3C’, red outline) in addition to increased
matrix secretion between the columns (arrows). Importantly, expres-
sion of the chick transgene in aggrecan-null embryos resulted in the
development of a distinct hypertrophic zone, in which the chondro-
cytes have assumed the characteristic enlarged, spherical cell shape
(Fig. 3C’, outlined by black box).
The initial studies on the cmd/cmd embryos postulated that
lethality in the mutants was due to inability to respire resulting
from tracheal collapse (Bell et al., 1986; Rittenhouse et al., 1978).
The cartilaginous rings of the trachea provide rigid structural
support to ensure airway patency, and chondrocytes in this type
of cartilage do not progress to hypertrophy and apoptosis, as seen
in growth plates (Fig. 3A C). We examined the tracheas of wild-
type, mutant, and rescue embryos (Fig. 3A”-C”) at 18.5 dpc. The
tracheal cartilage, as shown in a transverse section from the upper
third of the trachea, consists of a C-shaped ring of hyaline cartilage
connected at the dorsal aspect (D) by the trachealis muscle. The
lumen (L) of a wild-type trachea appears round and the epithelial
lining is smooth (Fig. 3A”, arrow head), demonstrating airway
patency. In contrast, the airway of a mutant embryo has extensive
epithelial folding (Fig. 3B”, arrow head), resulting in a star-shaped,
narrowed lumen, features that are consistent with severe tracheo-
malacia and stenosis which often cause collapse of the trachea
during expiration. Rescue embryos show signiﬁcantly improved
diameter of both the tracheal lumen and cartilaginous ring
structure, and a dramatic decrease in the degree of epithelial
folding, though some evidence of tracheomalacia remains
(Fig. 3C”, arrow head). In both mutant and rescue embryos, these
ﬁndings are associated with hypercellularity within the hyaline
cartilage and thickening of the submucosal layer (arrows).
Altered gene expression patterns in aggrecan-null growth plates are
partially restored with chick aggrecan transgene expression
In order to assess whether the histological changes observed in
mutant and rescue growth plates are associated with temporal
and/or spatial differences in gene expression patterns of key
embryonic growth plate regulatory components, mRNA in situ
hybridization was performed on serial sections of 18.5 dpc prox-
imal tibias, probing for several chondrocyte growth factors and
markers. As shown in Fig. 4G, wild-type embryos exhibit robust
Col10a1 expression restricted to hypertrophic chondrocytes (left
panel). However, the region of Col10a1 expression in mutants is
drastically decreased near the chondro-osseous junction (Fig. 4H),
implying that the loss of aggrecan has severely impacted the
normal hypertrophic differentiation of chondrocytes at this devel-
opmental stage. Expression of the chick aggrecan transgene in
rescue mice (Fig. 4I) results in a notable increase in the area and
intensity of Col10a1 expression in the hypertrophic zone compared
to mutants, congruent with the reappearance of enlarged, hyper-
trophic chondrocytes in this region (Fig. 3C’, box). The expression
pattern of Col2a1, the common cartilage marker expressed by all
committed chondrocytes, is not signiﬁcantly altered among wild-
type, mutant, and rescue cartilage tissue despite the variation in
growth plate size and chondrocyte morphology (Fig. 4A C), as was
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previously reported (Kimata et al., 1981). For this reason, the
Col2a1 promoter construct was used to drive expression of the
chick aggrecan transgene.
SOX9, a critical transcription factor controlling chondrocyte dif-
ferentiation, is expressed concomitantly with COL2A1 during carti-
lage development (Bi et al., 1999; Zhao et al., 1997). Similar to the
wild-type Col2a1 gene expression pattern, Sox9 transcripts in the
wild-type growth plate appear throughout the resting zone, and
peak expression is observed in the late-proliferative/prehypertrophic
chondrocytes, followed by an abrupt decline in expression in the
hypertrophic zone (Fig. 4D). However, mutant growth plates exhibit
diffuse, patchy expression of Sox9 with indiscriminate regions of
intense expression (Fig. 4E, arrow head) adjacent to areas of very low
levels of Sox9 (asterisk), unlike the pattern of Col2a1 expression.
Transgene expression in rescue mice restores the Sox9 expression
pattern in the resting and proliferative zone similar to that seen in
the wild type (Fig. 4F), although the presumptive zone of hypertro-
phy in rescue embryos does not demonstrate the typical decline in
Sox9 intensity seen in wild-type cartilage.
Gene expression patterns of Ihh, its receptor Ptch1, and Fgfr3, all of
which encode central factors controlling the rate of chondrocyte
differentiation to hypertrophy, are shown in Fig. 4J R. In wild-type
Fig. 3. Histological examination of mutant and rescue growth plate cytoarchitecture. Representative sections of 18.5 dpc femoral growth plates stained with hematoxylin
and eosin demonstrating chondrocyte morphology within each growth plate zone (A-C) for wild-type, mutant, and rescue embryos. (A’-C’) Higher magniﬁcation of the
proliferative and hypertrophic regions outlined in black boxes in top row. Red outlines highlight the columnar formation of proliferative chondrocytes, and the black box
denotes chondrocytes with hypertrophic morphology, both of which are absent in aggrecan-null growth plates. Note the hypercellularity and lack of extracellular matrix in
mutant embryos (arrow heads) compared to wild type and rescue (arrows). (A”-C”) Sections of cartilaginous rings from the upper third of the trachea, showing differences in
airway patency with and without aggrecan. R¼resting, P¼proliferative, H¼hypertrophic, L¼ lumen, D¼dorsal aspect.
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growth plates, expression of Ihh is restricted to the prehypertrophic
and early hypertrophic chondrocytes, as expected (Fig. 4J). Mutants
express extremely low levels of Ihh (Fig. 4K) in a single fragmented
row of weakly positive chondrocytes (inset), while expression of the
aggrecan transgene results in an increase in IHH mRNA production,
in a wider band with more chondrocytes, in the prehypertrophic/
hypertrophic region (Fig. 4L, inset), indicating that the presence of
aggrecan in the growth plate is imperative for normal Ihh expression.
Ptch1 encodes the receptor for IHH, is also a downstream target of
IHH pathway activation (Ingham, 1998), and Ptch1 transcripts are
normally found in the proliferative zone and in the perichondrium
ﬂanking this region, as shown in wild-type sections (Fig. 4M, arrows).
Although mutant growth plates display very little Ihh expression,
some Ptch1 transcripts are present in growth plate cartilage near the
perichondrium (Fig. 4N, arrow) and faint expression is detected
within the mid-growth plate. Unlike the expression observed in
growth plate cartilage, there appears to be relatively normal expres-
sion of Ptch1 within the bone marrow near the chondro-osseous
junction. Rescue growth plates display speciﬁc localization of Ptch1
transcripts in both the perichondrium and the proliferative zone,
similar to wild-type embryos (Fig. 4O, arrows), as well as within the
vascular invasion/ bone marrow regions.
The expression of Fgfr3, which encodes the receptor for the
negative regulators of chondrocyte proliferation in the growth
plate such as FGF9 (Garofalo et al., 1999) and FGF18 (Davidson
et al., 2005), is expressed by the proliferative zone chondrocytes in
the wild-type growth plate (Fig. 4P). In mutant growth plates, cells
centrally located near the presumptive hypertrophic region
express Fgfr3; however, the intensity of expression is notably
decreased compared to wild type (Fig. 4Q). In contrast, rescue
growth plates exhibit strong Fgfr3 signals in the proliferative and
early hypertrophic zones, an expression pattern that more closely
resembles that found in wild-type embryos (Fig. 4R). Taken
together, the data obtained from mRNA in situ hybridization
analysis suggest that the presence of aggrecan in the growth plate
extracellular matrix is fundamental to maintaining normal expres-
sion and spatial localization of essential regulators of chondrocyte
differentiation.
The apoptotic and proliferative phenotypes in the mutant growth
plate are ameliorated by aggrecan transgene expression
To further examine the cellular consequences associated with
aggrecan deletion in growth plate cartilage, we performed
Fig. 4. Expression pattern of growth plate transcripts by mRNA in situ hybridization. Representative expression analyses of Col2a1 (A-C), Sox9 (D-F), Col10a1 (G-I), Ihh (J-L),
Ptch1 (M-O), and Fgfr3 (P-R) transcripts in 18.5 dpc tibia sections fromwild-type, mutant, and rescue embryos. The panels demonstrating Ihh data contain insets that enlarge
the prehypertrophic/hypertrophic zone of expression. Results were observed consistently in ﬁve independent experiments with at least four embryos for each mRNA probed.
In situ hybridizations with DIG-labeled RNA probes were performed on 40 μm sections; cartilage elements are outlined for clarity.
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terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick
end labeling (TUNEL) staining and phospho-histone H3 (Ser10)
staining, which speciﬁcally labels cells entering the M phase of
mitosis, to examine apoptosis and proliferation, respectively. Wild-
type embryos exhibited very low overall levels of apoptosis at
18.5 dpc (Fig. 5A, D), while growth plates of mutant embryos
displayed a signiﬁcant 14-fold increase in cell death, with most of
the apoptotic cells appearing in the presumptive resting zone
adjacent to the perichondrium (Fig. 5B, D). The total percentage of
apoptotic chondrocytes in transgenic rescue mice was the normal
basal level found in wild-type mice (Fig. 5D); few apoptotic
chondrocytes were detected in the resting zone of rescue mice,
and TUNEL positivity was localized to the chondro-osseous junc-
tion (Fig. 5C). Upon closer examination of the resting zone mutant
cartilage (Fig. 5B’), many of the apoptotic cells are nucleated, as
indicated by the colocalization with DAPI (white arrows). There are
also clusters of “ghost” cells that retain no visible nuclear structure
yet exhibit strong TUNEL positivity, signifying the presence of
released nuclear contents within the chondrocyte lacunae (Fig. 5B’,
circle). The extranuclear staining observed was not due to non-
speciﬁc staining or autoﬂuorescence, as indicated by the negative
control (Fig. 5B”).
Concomitant with increased cell-death levels, mutant growth
plates (Fig. 6B”) display a signiﬁcant 57% decrease in proliferation
Fig. 5. Patterns of cell death in the growth plate of mutant and rescue embryos. Parafﬁn sections of 18.5 dpc embryonic femurs were analyzed for apoptotic cells using
TUNEL staining. Cartilaginous element limits are outlined in white. (A-C) Increased numbers of apoptotic cells are present in mutants, an occurrence not found in rescue
embryos. (A’-C’) Higher magniﬁcation of the white boxes outlined in A-C, demonstrating the aberrant cell death occurring in the resting zone of mutants but not in wild-type
or rescue embryos. (A”-C”) Negative control images of resting zone areas outlined. (D) Quantiﬁcation of total TUNEL-positive cells in the growth plate. n¼3–6 embryos/
genotype, npo0.001 vs. þ/þ , #po0.001 vs. cmdBc/cmdBc, one-way ANOVA with Tukey's post-hoc testing.
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compared to wild-type cartilage (Fig. 6A”), as seen by phospho-
histone H3 (PHH3) staining, which speciﬁcally identiﬁes cells
undergoing mitosis. Expression of the chick aggrecan transgene
in rescue mice signiﬁcantly increased the percentage of proliferat-
ing chondrocytes by more than twofold (Fig. 6C”), which restored
proliferation to levels observed in wild-type embryos (Fig. 6D).
Additionally, the DAPI nuclear stain in the proliferative zone of the
rescue embryos again demonstrates the change in morphology of
the chondrocytes from the round, immature appearance seen in
mutants (Fig. 6B, arrow head) to a ﬂattened morphology, including
columnar formation (Fig. 6C, arrow heads), which more resembles
wild-type embryonic growth plate cartilage (Fig. 6A, arrow head).
These results implicate a role for aggrecan in maintaining chon-
drocyte survival and proliferation in the developing growth plate.
Discussion
Speciﬁc ECM components are critical to skeletal development, as
they deﬁne the milieu for chondrocyte differentiation and matura-
tion, provide a scaffold to support the chondrocytes, and constitute a
medium in which signaling molecule gradients can differentially
affect ﬁelds of cells. Evidence that proper ECM composition is
essential to skeletal development emanates from the impact of
ECM-component-altering genetic defects, mutations which affect
cartilage formation and endochondral ossiﬁcation. Since the patho-
genesis is often complex and only partially explained by examining
the mutant phenotypes, we have taken the approach of attempting
correction of certain phenotypes which result from absence of
aggrecan, the predominant proteoglycan in cartilage ECM.
Our model uses the aggrecan cmdbc allele in the C57BL/6back-
ground to explore the molecular and morphological consequences
of aggrecan deletion on embryonic skeletal development in
a mammalian system, and a novel transgenic mouse line that
overexpresses the full-length chick aggrecan gene in chondrocytes
under the control of the mouse Col2a1 promoter (Zhou et al., 1995)
that mimics the temporal and spatial patterns of aggrecan
expression and partially rescues the cmdbc/cmdbc phenotype. Since
Col2a1 transcripts co-localize with aggrecan transcripts during
the same stage of limb bud development (Mallein-Gerin et al.,
1988), and the expression pattern of the cartilage-speciﬁc
Col2a1 mRNA transcripts is highly similar to that of aggrecan
Fig. 6. Proliferation in mutant and rescue embryonic growth plates. Embryonic femurs 18.5 dpc stained with DAPI and anti-phospho-histone H3 (PHH3) for analysis of
mitotic chondrocytes within the proliferative zone. (A-C) DAPI-stained proliferative chondrocytes demonstrate partial columnar formation in rescue embryos (red arrow
heads) compared to mutants. (A”-C”) Merged images show that rescue proliferative chondrocytes include double the percentage of pHH3-staining cells in the growth plate
compared to mutants, which is comparable to wild-type levels. (D) Quantiﬁcation of pHH3-positive proliferative chondrocytes in the growth plate. n¼3–6 embryos/
genotype, npo0.001 vs. þ/þ , #po0.01 vs. cmdBc/cmdBc, one-way ANOVA with Tukey's post-hoc testing.
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(Kosher et al., 1986), our choice of the Col2a1 promoter to drive
transgene expression is appropriate.
To our knowledge, this Col2a1-chick aggrecan transgenic
mouse possesses the largest transgene insert successfully cloned
(12.6 kb) and functionally expressed. Use of the rescue embryos,
which are hemizygous for the chick aggrecan transgene while
lacking mouse aggrecan, complements and expands upon our
previous studies in the chick investigating the critical roles of
chondroitin sulfate proteoglycans during development (Domowicz
et al., 2009). This approach also allows direct immunological
detection of the transgene product in mouse embryos. While
some differences exist between mouse and chick aggrecan
(Li et al., 1993), it is unknown to what extent these differences
may contribute to rescuing the cmdbc/cmdbc phenotype. As well,
the rate of aggrecan synthesis and turnover in chondrocytes differs
between cartilage zones (Shapses and Ratcliffe, 1994), and this
pattern may not precisely be duplicated in Col2a1-driven aggrecan
expression. Nonetheless, the presence of abundant S103L-positive
chick aggrecan protein in the ECM of transgenic mice and rescue
embryonic growth plates, as well as abundant levels of chondroi-
tin sulfate throughout the matrix provide evidence that chick
aggrecan protein is produced by transgenic mouse embryos, is
post-translationally modiﬁed, and is secreted to the ECM.
In analyzing the morphological and functional phenotypes, it
became clear that only certain of these were restored to wild-type
levels while others were only partially corrected, a result that has
proved to be as informative as a complete rescue would have been.
The observed outcome reﬂects the existence of many likely
sources of phenotypic variance, including cross-species differences
in aggrecan core protein primary structure with attendant possible
variations in GAG content; the cDNA source of the rescue aggrecan
altering/eliminating potential alternative splicing of exons; the
non-native regulation of the transgene's expression affecting the
rate and level of aggrecan production; although designed to
produce chick aggrecan in the appropriate cells at the desired
time, aggrecan expression may differ in subtle yet important ways
from the native pattern; and possible differences in interactions
with other ECM components, which could arise from one or more
of the aforementioned factors.
Aggrecan modulates chondrocyte differentiation
Rescue embryos demonstrate that considerable changes
occurred in both skeletal elements that develop through the process
of endochondral ossiﬁcation as well as permanent tracheal carti-
lage. Distinct changes in chondrocyte morphology and gene expres-
sion in the growth plate hypertrophic zone were associated with
the absence of aggrecan, most strikingly the diminished zone of
Col10a1-positive cells and lack of enlarged chondrocytes in cmdbc/
cmdbc embryos. Chick aggrecan transgene expression in such
mutants resulted in an expanded zone of Col10a1 expression and
enlarged chondrocyte morphology typical of the hypertrophic zone,
indicating that aggrecan plays a major role in modulating chon-
drocyte hypertrophic maturation in the developing growth plate,
although not fully establishing the morphology characteristic of a
wild-type hypertrophic zone. A recent hypothesis that the degree of
hypertrophic chondrocyte enlargement within a growth plate is
relative to the rate and extent of the linear growth of the element
(Cooper et al., 2013) also could explain why more substantial
element elongation was not observed in the rescue embryos.
An aggrecan-containing milieu is essential for chondrocyte survival
and proliferation
Growth plate elongation is dependent upon the proliferation and
maintenance of columnar chondrocytes and their intercalation into
columns, events which are absent in aggrecan-null cartilage. These
processes entail the production and secretion by prehypertrophic
growth plate chondrocytes of IHH, which ultimately acts with other
factors to slow the rate of hypertrophic maturation (Vortkamp et al.,
1996), regulate the length of column growth (Kobayashi et al.,
2005), and control the rate of proliferation (Minina et al., 2001). IHH
is expressed at very low levels by a single, fragmented layer of
growth plate chondrocytes in mutant tibial cartilage, and this low
level of IHH expression appears to be insufﬁcient to maintain
normal proliferation rates in mutants. In contrast, even minimal
levels of aggrecan enhance the number of IHH-expressing cells and
double the rate of cell division, effectively restoring proliferation
rates to wild-type levels. These results indicate that aggrecan
transgene expression inﬂuenced the survival or differentiation of
IHH-producing cells concomitant with restoration of proliferation
levels. However, the IHH-positive zone of chondrocytes remained
superimposed on the hypertrophic Col10a1-positive region, as
reported previously in the nanomelic chick (Domowicz et al.,
2009), suggesting that rapid conversion of IHH-producing chondro-
cytes to COL10A1-positive hypertrophic chondrocytes is still occur-
ring in rescue embryos and may be contributing to the incomplete
rescue phenotype. Although chick-aggrecan transgene expression in
rescue embryos did not fully restore normal Ihh expression, these
data support a role for aggrecan in promoting chondrocyte survival
and proliferation in the growth plate.
Lack of aggrecan leads to signaling defects
The absence of aggrecan in the growth plate may also inﬂuence
the signaling range of IHH in the growth plate. The transmem-
brane receptor Ptch1 is a downstream target of IHH-mediated
transcriptional activation that negatively regulates the propaga-
tion of IHH signaling (Chen, 1996) and is expressed in IHH target
cells located predominantly in the proliferative zone. Mutant
growth plates displayed very low levels of IHH mRNA; however,
the presence of Ptch1 transcripts suggests that IHH stimulation
may have occurred at an earlier time point or that the low amount
of IHH produced reaches alternative targets in the developing
element. This is supported by an observed shift in the localization
of Ptch1 expression to the trabecular bone, where robust staining
is present while only weak staining is visualized in the growth
plate cartilage, indicating that the range of IHH signaling in growth
plate cartilage is perturbed in the absence of aggrecan. In contrast,
rescue growth plates demonstrate PTCH1 signaling in the peri-
chondrium and presumptive proliferative zone in addition to the
bone marrow, suggesting improved IHH signaling range in carti-
lage accompanies aggrecan transgene expression. Collectively,
these data build upon our previous ﬁndings that normal
IHH gradient formation requires properly sulfated aggrecan
(Cortes et al., 2009). The decrease in FGFR3 mRNA observed in
cmdbc/cmdbc growth plates also suggests a loss of control of
hypertrophic differentiation. Increased expression of FGFR3, which
negatively regulates the rate of hypertrophic maturation (Garofalo
et al., 1999), within the proliferative zone of rescue embryos
suggests that some control over the maturation rate of growth
plate chondrocytes occurred, partially accounting for the appear-
ance of IHH-expressing cells and reestablishment of a distinct
hypertrophic zone.
SOX9 is an essential chondrocyte transcription factor directing
differentiation and columnar organization in the proliferative zone
(Dy et al., 2012). Mutant growth plate chondrocytes misexpress
SOX 9 throughout the growth plate, perturbing multiple stages of
chondrocyte growth and leading to loss of columnar organization,
early terminal maturation, and signiﬁcantly increased chondrocyte
apoptosis in resting zone cells. Interestingly, previous studies have
shown that mutants with Sox9 conditionally inactivated in resting
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chondrocytes during limb development display increased apopto-
sis (Ikegami et al., 2011), similar to what we observe in aggrecan-
null mutant embryos. Since SOX9 is one of the transcription
factors controlling aggrecan expression in chondrocytes (Sekiya
et al., 2000), it is possible that the apoptotic phenotype in
conditionally inactivated Sox9 mutants may be due in part to
reduced aggrecan synthesis. The misexpression and downregula-
tion of Sox9 in the mutant is notably reduced in rescue embryos,
which display very low levels of chondrocyte apoptosis. These
observations may indicate a feedback mechanism in which proper
matrix composition is required to maintain normal expression of
SOX9. The Col2a1 enhancer element within the transgene con-
structs in rescue embryos contains SOX9 binding sites that drive
efﬁcient transcription (Lefebvre et al., 1997); however, SOX9
expression in the rescue embryos is not completely restored to
wild-type levels, contributing to the incomplete rescue phenotype.
Further studies that highlight the temporal expression patterns of
IHH, PTCH1, SOX9, and FGFR3 expression at earlier time points
during limb development are needed to comprehensively assess
whether the gene expression changes observed are primary or
secondary to aggrecan deletion, which will allow a more thorough
understanding of the role of ECM proteins on the production and
distribution of these important chondrocyte factors.
In summary, we present evidence that the combined effects of
decreased proliferation, increased cell death, and altered gene
expression of growth plate regulators in aggrecan-deﬁcient mice
are ameliorated to varying degrees by the expression of a novel
Col2a1-driven chicken aggrecan transgene. These ﬁndings show
that aggrecan is an essential ECM component that affects chon-
drocyte survival, morphological transition, and gene expression in
growth plate cartilage, which may aid in elucidating therapeutic
targets for a variety of chondrodysplasias, arthritic diseases, and
other cartilage-related disorders associated with altered levels of
aggrecan.
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